ARCK Biologics
ARCK Biologics is developing a targeted, non-opioid biologic therapy for acute musculoskeletal pain that modulates pain mediators directly at the tissue level. The one-time treatment is designed to avoid systemic effects, addiction potential, and cognitive impairment while supporting faster recovery. The company plans to launch multi-site US Phase III clinical trials in 2026 across multiple acute MSK pain indications.
- Drug Discovery & Therapeutics
- Biotechnology
- Healthcare Technology
Funding
Founders
Founder details are not available yet.
Product
Problem
Acute musculoskeletal (MSK) pain is commonly managed with systemic analgesics, including opioids, which carry risks of addiction, cognitive impairment, organ failure, and other systemic side effects. Existing non-opioid options often provide incomplete relief or require repeated dosing, leaving a significant gap in care for patients who need effective, targeted pain modulation without systemic drug exposure.
Solution
ARCK Biologics delivers a targeted, non-opioid biologic therapy that engages damaged tissues directly at the site of injury to modulate acute pain mediators and support natural recovery. The therapy is designed as a one-time treatment that acts locally, producing no clinically significant systemic effects and avoiding the dependency and safety concerns associated with traditional analgesics. By focusing on tissue-level pain signaling, the platform aims to provide lasting relief and faster recovery while reducing reliance on opioids. The company is advancing this therapy through multi-site US Phase III clinical trials launching in 2026 to evaluate its safety, efficacy, and biologic impact across multiple acute MSK pain indications.
Target Audience
Primary customers are patients suffering from acute musculoskeletal pain and the healthcare providers—including orthopedic specialists, pain management physicians, and primary care clinicians—who seek safer, non-opioid treatment alternatives. The therapy also targets health systems and payers looking to reduce opioid-related complications and costs.
Features
- Targeted biologic platform engineered to modulate acute pain mediators at the tissue level where injury occurs
- One-and-done treatment design with no clinical systemic effects, no organ failure or bleeding risk, no addiction potential, and no cognitive impairment
- Non-opioid mechanism intended to reduce opioid reliance while supporting safer and faster pain relief
- Proprietary intellectual property covering the biologic composition and utilization strategy for MSK pain management
- Clinical development pipeline spanning multiple acute musculoskeletal pain indications with Phase III trials planned for 2026